Anti-Mouse GM-CSF Antibody (MP1-22E9) is a rat-derived inhibitory antibody against mouse GM-CSF that can specifically neutralize the GM-CSF factor. This antibody can be widely applied in research fields of cancer, infectious diseases, inflammatory diseases and immunology, including the research directions of cholangiocarcinoma, arthritis and others.

After 72 hours of treatment with Anti-Mouse GM-CSF Antibody (MP1-22E9), the cell viability of bone marrow-derived macrophages was significantly reduced[1].
Treatment with Anti-Mouse GM-CSF Antibody (MP1-22E9) at a concentration of 10 μg/mL for 30 minutes effectively promoted the differentiation and migration of myeloid-derived suppressor cells[5].

Intraperitoneal injection of Anti-Mouse GM-CSF Antibody (MP1-22E9) at a dose of 30 mg/kg once every 2 days for 4 weeks effectively inhibited tumor progression and prolonged the survival time of mice in a spontaneous intrahepatic cholangiocarcinoma mouse model[1].
Intraperitoneal injection of Anti-Mouse GM-CSF Antibody (MP1-22E9) at a dose of 800 μg on Mondays and Thursdays each week for 2 weeks reduced the level of angiogenesis in L2/IKKβca mice[2].
In a mouse model of spondyloarthritis, intraperitoneal injection of Anti-Mouse GM-CSF Antibody (MP1-22E9) at a dose of 250 μg inhibited myeloid hematopoiesis in the bone marrow and organ inflammation under two administration regimens: Regimen 1 involved administration one day before dextran injection, followed by twice a week for 7 weeks. Regimen 2 involved administration on the 9th day after disease induction, followed by twice a week until the 28th day[3].
Intraperitoneal injection of Anti-Mouse GM-CSF Antibody (MP1-22E9) at a dose of 200 μg once every 3 days suppressed the anti-tumor immune response in B16F10-OVA tumor-bearing mice by neutralizing the GM-CSF factor[4].
In HM-1 tumor-bearing mice, intraperitoneal injection of Anti-Mouse GM-CSF Antibody (MP1-22E9) at a dose of 100 μg twice a week exhibited significant anti-tumor activity[5].
For a mouse model of Clostridioides difficile infection, intraperitoneal injection of Anti-Mouse GM-CSF Antibody (MP1-22E9) at a dose of 250 μg, initiated one day before infection and administered once every other day for a total of 3 doses, exerted a significant anti-infective effect[6].

MP1-22E9

Mouse

Monoclonal

Unconjugated